These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 12242517)
21. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Vasile E; Masi G; Fornaro L; Cupini S; Loupakis F; Bursi S; Petrini I; Di Donato S; Brunetti IM; Ricci S; Antonuzzo A; Chiara S; Amoroso D; Andreuccetti M; Falcone A Br J Cancer; 2009 Jun; 100(11):1720-4. PubMed ID: 19436300 [TBL] [Abstract][Full Text] [Related]
22. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues. Brieau B; Dahan L; De Rycke Y; Boussaha T; Vasseur P; Tougeron D; Lecomte T; Coriat R; Bachet JB; Claudez P; Zaanan A; Soibinet P; Desrame J; Thirot-Bidault A; Trouilloud I; Mary F; Marthey L; Taieb J; Cacheux W; Lièvre A Cancer; 2015 Sep; 121(18):3290-7. PubMed ID: 26052689 [TBL] [Abstract][Full Text] [Related]
23. Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. Lee KW; Kim YJ; Lee KH; Han SW; Kim TY; Oh DY; Im SA; Kim TY; Bang YJ; Choi IS; Kim JH Cancer Chemother Pharmacol; 2014 Sep; 74(3):447-55. PubMed ID: 24947909 [TBL] [Abstract][Full Text] [Related]
24. Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients. Bitossi R; Sculli CM; Tampellini M; Alabiso I; Brizzi MP; Ferrero A; Ottone A; Bellini E; Gorzegno G; Berruti A; Dogliotti L Anticancer Res; 2008; 28(5B):3055-60. PubMed ID: 19031956 [TBL] [Abstract][Full Text] [Related]
25. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. Chllamma MK; Cook N; Dhani NC; Giby K; Dodd A; Wang L; Hedley DW; Moore MJ; Knox JJ Br J Cancer; 2016 Sep; 115(6):649-54. PubMed ID: 27467054 [TBL] [Abstract][Full Text] [Related]
26. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. Martinez J; Martin C; Chacon M; Korbenfeld E; Bella S; Senna S; Richardet E; Coppola F; Bas C; Hidalgo J; Escobar E; Reale M; Smilovich AM; Wasserman E Am J Clin Oncol; 2006 Feb; 29(1):45-51. PubMed ID: 16462502 [TBL] [Abstract][Full Text] [Related]
27. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Yamaguchi T; Machida N; Morizane C; Kasuga A; Takahashi H; Sudo K; Nishina T; Tobimatsu K; Ishido K; Furuse J; Boku N; Okusaka T Cancer Sci; 2014 Sep; 105(9):1176-81. PubMed ID: 24975505 [TBL] [Abstract][Full Text] [Related]
28. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797 [TBL] [Abstract][Full Text] [Related]
29. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Garufi C; Torsello A; Tumolo S; Ettorre GM; Zeuli M; Campanella C; Vennarecci G; Mottolese M; Sperduti I; Cognetti F Br J Cancer; 2010 Nov; 103(10):1542-7. PubMed ID: 20959822 [TBL] [Abstract][Full Text] [Related]
30. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. Santini D; Vincenzi B; La Cesa A; Caricato M; Schiavon G; Spalletta B; Di Seri M; Coppola R; Rocci L; Tonini G Oncology; 2005; 69(1):27-34. PubMed ID: 16088232 [TBL] [Abstract][Full Text] [Related]
31. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. Lorgis V; Chauffert B; Gentil J; Ghiringhelli F Anticancer Res; 2012 Sep; 32(9):4125-30. PubMed ID: 22993372 [TBL] [Abstract][Full Text] [Related]
32. The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy. Popov I; Milicević M; Radosević-Jelić Lj Acta Chir Iugosl; 2008; 55(4):11-6. PubMed ID: 19245134 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Bidard FC; Tournigand C; André T; Mabro M; Figer A; Cervantes A; Lledo G; Bengrine-Lefevre L; Maindrault-Goebel F; Louvet C; de Gramont A Ann Oncol; 2009 Jun; 20(6):1042-7. PubMed ID: 19153116 [TBL] [Abstract][Full Text] [Related]
34. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma. Ellenrieder V; König A; Seufferlein T Digestion; 2016; 94(1):44-9. PubMed ID: 27438590 [TBL] [Abstract][Full Text] [Related]
35. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367 [TBL] [Abstract][Full Text] [Related]
36. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies. Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855 [TBL] [Abstract][Full Text] [Related]
37. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer. Hwang IG; Jang JS; Oh SY; Rho MH; Lee S; Park YS; Park JO; Nam EM; Lee HR; Jun HJ; Chi KC Cancer Chemother Pharmacol; 2015 Apr; 75(4):757-62. PubMed ID: 25677446 [TBL] [Abstract][Full Text] [Related]
38. Weekly High-dose 5-Fluorouracil as 24-hour Infusion Combined with Sodium Folinic Acid (AIO regimen) Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer (CRC). Wein A; Siebler J; Wolff K; Ostermeier N; Busse D; Hagel A; Koch F; Merx K; Neurath MF; Hofheinz RD Anticancer Res; 2017 Jul; 37(7):3771-3779. PubMed ID: 28668873 [TBL] [Abstract][Full Text] [Related]
39. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer]. Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of oxaliplatin and non-hematological toxicity in metastatic gastrointestinal cancer patients treated with chronomodulated oxaliplatin, 5-FU and sodium folinate in a pilot investigation. Merkel U; Farker K; Wedding U; Roskos M; Hippius M; Höffken K; Hoffmann A Int J Clin Pharmacol Ther; 2006 Mar; 44(3):128-34. PubMed ID: 16550735 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]